The Journal of Immunology, Vol 159, Issue 3 1383-1392, Copyright © 1997 by American Association of Immunologists

ARTICLES

The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection

BD Livingston, C Crimi, H Grey, G Ishioka, FV Chisari, J Fikes, H Grey, RW Chesnut and A Sette
Cytel Corp., San Diego, CA 92121, USA. brian_livingston@cytelcorp.com

We have previously described the development of a lipopeptide-based vaccine, Theradigm-HBV, capable of inducing CTL responses in humans. This vaccine incorporates the HLA-A2.1-restricted CTL epitope hepatitis B core Ag 18-27, linked to the universal helper T lymphocyte (HTL) epitope tetanus toxoid (TT) 830-843. Herein, we report the results of a phase I trial designed to examine the effects of Theradigm-HBV dose and regimen on the magnitude and duration of the memory CTL response. A total of four injections of up to 5 mg/dose were found to be a safe and effective means of generating substantial memory CTL responses. Precursor frequency analysis demonstrated CTL responses of similar magnitude to those previously observed in patients who successfully cleared hepatitis B virus infection and to influenza-specific memory CTL responses induced by natural exposure to influenza virus. Theradigm- HBV induced CTL responses that persisted for more than 9 months after the last injection. HTL responses were associated with significant CTL responses, and sustained HTL activity was necessary for development of persistent memory CTL activity. These results represent the first demonstration of the importance of HTL activity for development of long- lived memory CTL responses in humans. In conclusion, our results show that lipopeptides safely induce specific CTL activity in humans of such magnitude and persistence as to be of potential therapeutic significance.

This article has been cited by other articles:

				E. Depla, A. Van der Aa, B. D. Livingston, C. Crimi, K. Allosery, V. De Brabandere, J. Krakover, S. Murthy, M. Huang, S. Power, et al. Rational Design of a Multiepitope Vaccine Encoding T-Lymphocyte Epitopes for Treatment of Chronic Hepatitis B Virus Infections J. Virol., January 1, 2008; 82(1): 435 - 450. [Abstract] [Full Text] [PDF]

				J. M. Calvo-Calle, G. A. Oliveira, C. O. Watta, J. Soverow, C. Parra-Lopez, and E. H. Nardin A Linear Peptide Containing Minimal T- and B-Cell Epitopes of Plasmodium falciparum Circumsporozoite Protein Elicits Protection against Transgenic Sporozoite Challenge Infect. Immun., December 1, 2006; 74(12): 6929 - 6939. [Abstract] [Full Text] [PDF]

				E. Mizukoshi, J. Sidney, B. Livingston, M. Ghany, J. H. Hoofnagle, A. Sette, and B. Rehermann Cellular Immune Responses to the Hepatitis B Virus Polymerase J. Immunol., November 1, 2004; 173(9): 5863 - 5871. [Abstract] [Full Text] [PDF]

				H. Gahery-Segard, G. Pialoux, S. Figueiredo, C. Igea, M. Surenaud, J. Gaston, H. Gras-Masse, J.-P. Levy, and J.-G. Guillet Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized J. Virol., October 15, 2003; 77(20): 11220 - 11231. [Abstract] [Full Text] [PDF]

				M. Andrieu, J.-F. Desoutter, E. Loing, J. Gaston, D. Hanau, J.-G. Guillet, and A. Hosmalin Two Human Immunodeficiency Virus Vaccinal Lipopeptides Follow Different Cross-Presentation Pathways in Human Dendritic Cells J. Virol., December 20, 2002; 77(2): 1564 - 1570. [Abstract] [Full Text] [PDF]

				C. La Rosa, Z. Wang, J. C. Brewer, S. F. Lacey, M. C. Villacres, R. Sharan, R. Krishnan, M. Crooks, S. Markel, R. Maas, et al. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice Blood, November 15, 2002; 100(10): 3681 - 3689. [Abstract] [Full Text] [PDF]

				W. Paster, M. Kalat, M. Zehetner, and T. Schweighoffer Structural Elements of a Protein Antigen Determine Immunogenicity of the Embedded MHC Class I-Restricted T Cell Epitope J. Immunol., September 15, 2002; 169(6): 2937 - 2946. [Abstract] [Full Text] [PDF]

				G. Deliyannis, D. C. Jackson, N. J. Ede, W. Zeng, I. Hourdakis, E. Sakabetis, and L. E. Brown Induction of Long-Term Memory CD8+ T Cells for Recall of Viral Clearing Responses against Influenza Virus J. Virol., March 27, 2002; 76(9): 4212 - 4221. [Abstract] [Full Text] [PDF]

				T. U. Vogel, B. E. Beer, J. zur Megede, H.-G. Ihlenfeldt, G. Jung, S. Holzammer, D. I. Watkins, J. D. Altman, R. Kurth, and S. Norley Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge J. Gen. Virol., January 1, 2002; 83(1): 81 - 91. [Abstract] [Full Text] [PDF]

				E. H. Nardin, J. M. Calvo-Calle, G. A. Oliveira, R. S. Nussenzweig, M. Schneider, J.-M. Tiercy, L. Loutan, D. Hochstrasser, and K. Rose A Totally Synthetic Polyoxime Malaria Vaccine Containing Plasmodium falciparum B Cell and Universal T Cell Epitopes Elicits Immune Responses in Volunteers of Diverse HLA Types J. Immunol., January 1, 2001; 166(1): 481 - 489. [Abstract] [Full Text] [PDF]

				H. Gahéry-Ségard, G. Pialoux, B. Charmeteau, S. Sermet, H. Poncelet, M. Raux, A. Tartar, J.-P. Lévy, H. Gras-Masse, and J.-G. Guillet Multiepitopic B- and T-Cell Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine J. Virol., February 15, 2000; 74(4): 1694 - 1703. [Abstract] [Full Text]

				E. Loing, M. Andrieu, K. Thiam, D. Schorner, K.-H. Wiesmuller, A. Hosmalin, G. Jung, and H. Gras-Masse Extension of HLA-A*0201-Restricted Minimal Epitope by N{epsilon}-Palmitoyl-lysine Increases the Life Span of Functional Presentation to Cytotoxic T Cells J. Immunol., January 15, 2000; 164(2): 900 - 907. [Abstract] [Full Text] [PDF]

				T. Arichi, T. Saito, M. E. Major, I. M. Belyakov, M. Shirai, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model PNAS, January 4, 2000; 97(1): 297 - 302. [Abstract] [Full Text] [PDF]

				J. A. Zaia, J.G. P. Sissons, S. Riddell, D. J. Diamond, M.R. Wills, A.J. Carmichael, M.P. Weekes, M. Gandhi, C. La Rosa, M. Villacres, et al. Status of Cytomegalovirus Prevention and Treatment in 2000 Hematology, January 1, 2000; 2000(1): 339 - 355. [Abstract] [Full Text] [PDF]

				L. Mortara, H. Gras-Masse, C. Rommens, A. Venet, J.-G. Guillet, and I. Bourgault-Villada Type 1 CD4+ T-Cell Help Is Required for Induction of Antipeptide Multispecific Cytotoxic T Lymphocytes by a Lipopeptidic Vaccine in Rhesus Macaques J. Virol., May 1, 1999; 73(5): 4447 - 4451. [Abstract] [Full Text]

				G. Y. Ishioka, J. Fikes, G. Hermanson, B. Livingston, C. Crimi, M. Qin, M. France del Guercio, C. Oseroff, C. Dahlberg, J. Alexander, et al. Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes J. Immunol., April 1, 1999; 162(7): 3915 - 3925. [Abstract] [Full Text] [PDF]

				B. D. Livingston, J. Alexander, C. Crimi, C. Oseroff, E. Celis, K. Daly, L. G. Guidotti, F. V. Chisari, J. Fikes, R. W. Chesnut, et al. Altered Helper T Lymphocyte Function Associated with Chronic Hepatitis B Virus Infection and its Role in Response to Therapeutic Vaccination in Humans J. Immunol., March 1, 1999; 162(5): 3088 - 3095. [Abstract] [Full Text] [PDF]

				K.-M. Chang, N. H. Gruener, S. Southwood, J. Sidney, G. R. Pape, F. V. Chisari, and A. Sette Identification of HLA-A3 and -B7-Restricted CTL Response to Hepatitis C Virus in Patients with Acute and Chronic Hepatitis C J. Immunol., January 15, 1999; 162(2): 1156 - 1164. [Abstract] [Full Text] [PDF]